- NITRIC OXIDE-RELEASING PRODRUG MOLECULE
-
Provided are a type of compounds that can be used for treating cardiovascular diseases and compositions containing the compounds. The compounds and the compositions can improve lipid metabolism disorders by increasing high-density lipoprotein cholesterol in blood; in addition, the compounds and the compositions can also release nitric oxide, and reduce the onset risk of cardiovascular diseases by means of relaxing blood vessels, lowering blood pressure, inhibiting platelet adhesion and aggregation and maintaining vascular tension, and thus play an important role in preventing and treating the occurrence and development of cardiovascular diseases.
- -
-
Paragraph 0064
(2018/08/01)
-
- CARBACEPHEM β-LACTAM ANTIBIOTICS
-
Carbacephem -lactam antibiotics having structure (I) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar1, Ar2, R1 and R2 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.
- -
-
Page/Page column 75
(2010/04/06)
-
- CARBACEPHEM BETA-LACTAM ANTIBIOTICS
-
Carbacephem β-lactam antibiotics having chemical structures (I) and (II) are disclosed: including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R6 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.
- -
-
Page/Page column 60
(2010/11/05)
-
- CARBACEPHEM β-LACTAM ANTIBIOTICS
-
Carbacephem β-lactam antibiotics having the following chemical structures (I) and (II) are disclosed, including stereoisomers, pharmaceutically acceptable salts, esters and prodrugs thereof, wherein Ar2, R1, R2 and R3 are as defined herein. The compounds are useful for the treatment of bacterial infections, in particular those caused by methicillin-resistant Staphylococcus spp.
- -
-
Page/Page column 89
(2009/05/30)
-
- NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE AT1 AND ETA RECEPTORS
-
The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.
- -
-
Page/Page column 85; 93-94; 115-116; 131; 139; 152; 164; 176; 187
(2010/11/28)
-
- Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives
-
The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay.
- Mader, Mary M.,Shih, Chuan,Considine, Eileen,De Dios, Alfonso,Grossman, Cora Sue,Hipskind, Philip A.,Lin, Ho-Shen,Lobb, Karen L.,Lopez, Beatriz,Lopez, Jose E.,Cabrejas, Luisa M. Martin,Richett, Michael E.,White, Wesley T.,Cheung, Yiu-Yin,Huang, Zhongping,Reilly, John E.,Dinn, Sean R.
-
p. 617 - 620
(2007/10/03)
-
- Keratinocyte growth inhibitors and hydroxamic acid derivatives
-
This invention relates to a keratinocyte-proliferation inhibitor comprising as active ingredient a compound having an activity of inhibiting the solubilization of heparin-binding EGF-like growth factor bound to cell membranes and a compound of the formula (I); or pharmaceutically acceptable salt thereof, wherein R1, R2, R3 are hydrogen atom or alkyl and X is substituted benzene or the like.
- -
-
-
- Sulfonylureas: A new class of cancer chemotherapeutic agents
-
This study summarizes the antitumor properties of a number of sulofenur thiophene analogs against subcutaneously implanted 6C3HED lymphosarcoma with structural modification of the aryl moiety of the sulfonamide portion of the diarylsulfonylureas. The spectrum of activity of N-(p-chlorophenyl)-N'-[(5- methoxy-2-thienyl)sulfonyl]urea in the HXGC3, VRC5, CX-1, and LX-1 cell lines is also presented.
- Mohamadi,Spees,Grindey
-
p. 3012 - 3016
(2007/10/02)
-
- The Use of N,N-Dimethylformamide-Sulfonyl Chloride Complex for the Preparation of Thiophenesulfonyl Chlorides
-
A 1:1 N,N-dimethylformamide-SO2Cl2 complex was found to be a useful agent for the one-step preparation of thiophenesulfonyl chlorides.
- Sone, Tyo,Abe, Yukio,Sato, Norio,Ebina, Manabu
-
p. 1063 - 1064
(2007/10/02)
-